Core Insights - The increasing prevalence of dry eye patients in China highlights a gap in public understanding, which remains focused on temporary relief through eye drops rather than addressing underlying issues [2] - The launch of the innovative drug, the tobramycin nasal spray, represents a shift towards a "repair-type" strategy for treating dry eye, aiming to restore tear gland function and enhance natural tear production [2][4] - The conference held on October 25 showcased the new nasal spray and brought together leading experts to discuss advancements in dry eye treatment and the establishment of a healthy ocular ecosystem [4] Group 1: Medical Insights - Experts from Xiamen University and Huazhong University of Science and Technology discussed typical symptoms and high-risk groups for dry eye, emphasizing the need for new treatment methods that actively stimulate tear production [1] - Clinical evidence presented by Zhejiang University highlighted the long-term benefits of the nasal spray in promoting secretion and providing rapid anti-inflammatory effects [1] - The transition from "supplementing water" to "producing water" in dry eye treatment was analyzed, focusing on the innovative mechanism of the nasal spray that activates tear secretion through neural stimulation [1] Group 2: Industry Developments - The traditional approach of using artificial tears is criticized for its limitations, including dependency and potential suppression of natural tear production, which can worsen the condition over time [2] - The launch of the nasal spray aligns with the strategic vision of the company to enhance its portfolio in ophthalmology, with plans for multiple new drug approvals in the next three years targeting various eye conditions [2]